Efficacy of Bioactive Glass vs. Xenograft in Maxillary Sinus Augmentation
Launched by SUEZ CANAL UNIVERSITY · Aug 14, 2025
Trial Information
Current as of August 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different materials used to help rebuild bone in the upper jaw (specifically, the area under the sinus) for people who need dental implants but have lost bone in that region. The researchers want to see how well a new material called bioactive glass works compared to a more traditional material made from animal bone (called a xenograft). They will look at the amount of new bone grown and how healthy it is, using special imaging scans and, if possible, tissue samples.
People who might join this study are adults between 20 and 65 years old who need bone added to their upper jaw because they don’t have enough bone to support dental implants. To qualify, they should be generally healthy, have limited bone height in the back of the upper jaw, and be able to attend follow-up visits. The study will not include people with certain health issues that affect bone healing, heavy smokers, those with active sinus problems, or women who are pregnant or breastfeeding. Participants will be randomly assigned to receive either the bioactive glass or the traditional bone graft during their sinus surgery, and their bone growth will be monitored over time using detailed scans. This research is taking place at the Faculty of Dentistry, Suez Canal University, and is not yet open for enrollment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients requiring maxillary sinus floor augmentation for dental implant placement.
- • Residual alveolar bone height ≤ 4 mm in posterior maxilla (SA4 classification).
- • Age between 20 to 65 years.
- • Good general health and able to attend scheduled follow-up visits.
- • Signed written informed consent.
- Exclusion Criteria:
- • Presence of systemic conditions that could affect bone healing (e.g., uncontrolled diabetes, osteoporosis).
- • History of radiotherapy in the head and neck region.
- • Heavy smoking (more than 10 cigarettes/day).
- • Active sinus pathology or previous sinus surgery.
- • Pregnant or breastfeeding women.
- • Use of medications affecting bone metabolism (e.g., bisphosphonates or corticosteroids).
- • Poor oral hygiene or untreated periodontal disease.
About Suez Canal University
Suez Canal University is a distinguished academic institution dedicated to advancing medical research and education in the region. As a clinical trial sponsor, the university focuses on conducting innovative studies that aim to enhance patient care and outcomes. Leveraging its strong network of healthcare professionals and state-of-the-art facilities, Suez Canal University fosters collaboration between researchers and clinicians to explore new therapeutic approaches and validate clinical practices. Committed to ethical standards and scientific rigor, the university plays a pivotal role in contributing to the global body of medical knowledge and improving healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mohamed A Elsholkamy, Professor
Principal Investigator
Suez Canal University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported